Radioguided surgery with radiolabeled somatostatin analogues in neuroendocrine tumors: Case report

Authors

DOI:

https://doi.org/10.22516/25007440.604

Keywords:

Neuroendocrine Tumors, Nuclear Medicine, Radioguided Surgery, Positron Emission Tomography

Abstract

Introduction: The best treatment for neuroendocrine tumors is complete resection of the tumor, lymph nodes, and even distant metastases in selected cases. Sometimes, the primary tumor is small and difficult to detect before surgery, or its relapses may be difficult to locate in the fibrosis field due to previous surgeries or treatments. Although radioguided surgery allows for additional intraoperative localization, it has yet to be widely used in neuroendocrine tumors.

Case report: A 59-year-old patient with a history of atypical resection of duodenum and pancreas due to grade 2 neuroendocrine tumor of the duodenum one year earlier. On 68Ga-DOTANOC PET/CT, a node with somatostatin receptor overexpression was found in the mesentery, with no other distant lesions. Due to the surgical history and the difficulty in visualizing the lesion on anatomical images (MRI), it was decided to perform the radioguided surgery. During the preoperative period, 15 mCi of 99mTc-HYNIC-TOC were administered verifying good uptake in the ganglion. Following the initial dissection, a gamma probe was used, detecting 5 times more activity in the ganglion than in adjacent tissues, allowing for localization and resection. The patient’s progress was satisfactory, and one year later there is no evidence of relapse.

Conclusion: Although radioguided surgery is not commonly used in the intraoperative location of neuroendocrine tumors, it is a viable option in some situations, such as the one presented here, because it allows for intraoperative detection and full resection.

Downloads

Download data is not yet available.

Author Biographies

Sarai Elena Moron Araujo, Fundación Universitaria Sanitas

Residente de IV año de Medicina Nuclear, Bogotá, Colombia.

Oscar Alexander Guevara Cruz, Instituto Nacional de Cancerología

Cirujano Hepato Pancreato Biliar. Universidad Nacional de Colombia. Bogotá, Colombia.

Adriana Jeruzza Rosales Morales, Fundación Universitaria de Ciencias de la Salud

Fellow de Medicina Nuclear, Bogotá, Colombia.

Julián Gilberto Rojas Camacho, Instituto Nacional de Cancerología

Médico Nuclear, Bogotá, Colombia

References

García-Talavera P, Ruano R, Rioja ME, Cordero JM, Razola P, Vidal-Sicart S. Cirugía radioguíada de tumores neuroendocrinos. Revisión de la literatura. Rev Esp Med Nucl Imagen Mol. 2014;33(6):358-65. https://doi.org/10.1016/j.remn.2014.07.004

Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O’Connor J, O’Toole D, Krenning E, Reed N, Kianmanesh R; Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology. 2016;103(2):125-38. https://doi.org/10.1159/000443170

Kaemmerer D, Prasad V, Daffner W, Haugvik SP, Senftleben S, Baum RP, Hommann M. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. Clin Nucl Med. 2012;37(2):142-

https://doi.org/10.1097/RLU.0b013e3182291de8

El Lakis M, Gianakou A, Nockel P, Wiseman D, Tirosh A, Quezado MA, Patel D, Nilubol N, Pacak K, Sadowski SM, Kebebew E. Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. JAMA Surg. 2019;154(1):40-45. https://doi.org/10.1001/jamasurg.2018.3475

Gulec SA, Baum R. Radio-guided surgery in neuroendocrine tumors. J Surg Oncol. 2007;96(4):309-15. https://doi.org/10.1002/jso.20868

Valdés Olmos RA, Vidal-Sicart S, Manca G, Mariani G, León-Ramírez LF, Rubello D, Giammarile F. Advances in radioguided surgery in oncology. Q J Nucl Med Mol Imaging. 2017;61(3):247-70. https://doi.org/10.23736/S1824-4785.17.02995-8

Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D; CARE Group*. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development. Glob Adv Health Med. 2013;2(5):38-43. https://doi.org/10.7453/gahmj.2013.008

Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer. 2012;3:292-302. https://doi.org/10.7150/jca.4502

Sadowski SM, Millo C, Neychev V, Aufforth R, Keutgen X, Glanville J, Alimchandani M, Nilubol N, Herscovitch P, Quezado M, Kebebew E. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2015;22 Suppl 3(Suppl 3):S676-82. https://doi.org/10.1245/s10434-015-4857-9

Makridis C, Oberg K, Juhlin C, Rastad J, Johansson H, Lörelius LE, Akerström G. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14(3):377-83; discussion 384-5. https://doi.org/10.1007/BF01658532

Adams S, Baum RP, Hertel A, Wenisch HJ, Staib-Sebler E, Herrmann G, Encke A, Hör G. Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med. 1998;39(7):1155-60.

Baum RP, Sandrucci S, Adams S. Radioguided Surgery of Neuroendocrine Tumors. En: Mariani G, Giuliano AE, Strauss HW (editores). Radioguided Surgery: A Comprehensive Team Approach. 1.a edición. Nueva York: Springer; 2008. p. 252-61. https://doi.org/10.1007/978-0-387-38327-9_24

Hall NC, Bluemel C, Vidal-Sicart S, Povoski SP. Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumors. En: Herrmann K, Nieweg O, Povoski SP (editores). Radioguided Surgery: Current Applications and Innovative Directions in Clinical Practice. 1.a edición. Nueva York: Springer; 2016. p. 299-311. https://doi.org/10.1007/978-3-319-26051-8_19

Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000;27(6):628-37. https://doi.org/10.1007/s002590050556

Ambrosini V, Fanti S. Radioguided surgery with 68Ga-DOTATATE for patients with neuroendocrine tumors. Hepatobiliary Surg Nutr. 2020;9(1):67-69. https://doi.org/10.21037/hbsn.2019.06.04

Figura 1. Flujograma de la evolución clínica del paciente

Published

2021-04-21

How to Cite

Moron Araujo, S. E., Guevara Cruz, O. A., Rosales Morales, A. J., & Rojas Camacho, J. G. (2021). Radioguided surgery with radiolabeled somatostatin analogues in neuroendocrine tumors: Case report. Revista Colombiana De Gastroenterología, 36(Supl. 1), 78–84. https://doi.org/10.22516/25007440.604

Altmetric

Crossref Cited-by logo
Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code